{
    "info": {
        "nct_id": "NCT05869955",
        "official_title": "A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy or Systemic Sclerosis (Breakfree-1)",
        "inclusion_criteria": "Inclusion Criteria\n\n- Diagnosis of Systemic Lupus Erythematosus (SLE) defined as follows:.\n\ni) Fulfilling the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria of SLE.\n\nii) Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), or anti-Sm antibodies at screening.\n\n- SLE disease activity.\n\ni) Active disease at screening, with recent ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system).\n\nii) Inadequate response to glucocorticoids and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.\n\n- Diagnosis of Idiopathic Inflammatory Myopathy (IIM) defined as follows:.\n\ni) Fulfilling the 2017 EULAR/ACR classification criteria for probable or definite IIM.\n\nii) Participant diagnosed with the following IIM subgroups: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and polymyositis (PM).\n\niii) Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.\n\n- IIM disease activity.\n\ni) Severe muscle AND/OR skin involvement.\n\nii) Proof of activity as documented by:.\n\nA. An active myositis-associated rash OR.\n\nB. A recent muscle biopsy OR.\n\nC. An elevated CK > 3 times the upper limit of normal OR.\n\nD. Participants diagnosed IIM AND progressive Interstitial Lung Disease (ILD) on high-resolution computed tomography (HRCT)\n\niii) Inadequate response to glucocorticoids and at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, leflunomide, IVIG, and rituximab.\n\n- Diagnosis of Systemic Sclerosis (SSc) defined as follows:.\n\ni) Fulfilling 2013 EULAR/ACR classification criteria for SSc.\n\nii) Antinuclear Antibody (ANA) positive at screening or prior to screening.\n\n- SSc disease activity.\n\ni) Participants diagnosed with diffuse cutaneous SSc OR diffuse or limited cutaneous SSc AND progressive ILD, AND.\n\nii) Inadequate response to at least 1 of the following treatments used for at least 3 months: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, or intravenous immunoglobulins (IVIG).\n\nExclusion Criteria\n\n* Diagnosis of drug-induced SLE rather than idiopathic SLE.\n* Other systemic autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded.\n* SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, are excluded.\n* Present or recent clinically significant CNS pathology, within 12 months.\n* IIM disease activity.\n\n  i) Other forms of IIM: Inclusion Body Myositis, Amyopathic DM, any form of juvenile myositis.\n\nii) Myositis other than IIM, eg, drug-induced myositis and PM associated with HIV.\n\niii) Participants with severe muscle damage (Physician VAS for muscle damage in Myositis Damage Index > 7 cm on a 10 cm scale), permanent weakness due to a non-IIM cause (eg, stroke), or myositis with cardiac involvement.\n\n- SSc disease activity.\n\ni) SSc related PAH requiring active treatment.\n\nii) Rapidly progressive SSc related lower GI (small and large intestines) involvement (requiring parenteral nutrition); active gastric antral vascular ectasia.\n\niii) Prior scleroderma renal crisis.\n\n- Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* IIM disease activity.",
            "criterions": [
                {
                    "exact_snippets": "IIM disease activity",
                    "criterion": "IIM disease activity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Diagnosis of Idiopathic Inflammatory Myopathy (IIM) defined as follows:.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Idiopathic Inflammatory Myopathy (IIM)",
                    "criterion": "Idiopathic Inflammatory Myopathy (IIM) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Active disease at screening, with recent ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system).",
            "criterions": [
                {
                    "exact_snippets": "Active disease at screening",
                    "criterion": "disease activity at screening",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system)",
                    "criterion": "major organ system involvement with BILAG A score",
                    "requirements": [
                        {
                            "requirement_type": "number of major organ systems with BILAG A score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "major organ system"
                            }
                        },
                        {
                            "requirement_type": "organ system exclusion",
                            "expected_value": [
                                "musculoskeletal",
                                "mucocutaneous",
                                "constitutional"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Myositis other than IIM, eg, drug-induced myositis and PM associated with HIV.",
            "criterions": [
                {
                    "exact_snippets": "Myositis other than IIM",
                    "criterion": "myositis",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "not idiopathic inflammatory myopathy (IIM)"
                        }
                    ]
                },
                {
                    "exact_snippets": "drug-induced myositis",
                    "criterion": "myositis",
                    "requirements": [
                        {
                            "requirement_type": "cause",
                            "expected_value": "drug-induced"
                        }
                    ]
                },
                {
                    "exact_snippets": "PM associated with HIV",
                    "criterion": "polymyositis (PM)",
                    "requirements": [
                        {
                            "requirement_type": "association",
                            "expected_value": "HIV"
                        }
                    ]
                }
            ]
        },
        {
            "line": "C. An elevated CK > 3 times the upper limit of normal OR.",
            "criterions": [
                {
                    "exact_snippets": "An elevated CK > 3 times the upper limit of normal",
                    "criterion": "creatine kinase (CK) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "times the upper limit of normal"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii) Prior scleroderma renal crisis.",
            "criterions": [
                {
                    "exact_snippets": "Prior scleroderma renal crisis.",
                    "criterion": "scleroderma renal crisis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- SLE disease activity.",
            "criterions": [
                {
                    "exact_snippets": "SLE disease activity",
                    "criterion": "SLE disease activity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Diagnosis of Systemic Sclerosis (SSc) defined as follows:.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Systemic Sclerosis (SSc)",
                    "criterion": "Systemic Sclerosis (SSc) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Antinuclear Antibody (ANA) positive at screening or prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Antinuclear Antibody (ANA) positive at screening or prior to screening.",
                    "criterion": "Antinuclear Antibody (ANA)",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "prior to screening"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Participant diagnosed with the following IIM subgroups: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and polymyositis (PM).",
            "criterions": [
                {
                    "exact_snippets": "Participant diagnosed with the following IIM subgroups: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and polymyositis (PM).",
                    "criterion": "idiopathic inflammatory myopathy (IIM) subgroup diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "dermatomyositis (DM)",
                                "immune-mediated necrotizing myopathy (IMNM)",
                                "anti-synthetase syndrome (ASyS)",
                                "polymyositis (PM)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Severe muscle AND/OR skin involvement.",
            "criterions": [
                {
                    "exact_snippets": "Severe muscle",
                    "criterion": "muscle involvement",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "Severe ... skin involvement",
                    "criterion": "skin involvement",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Participants diagnosed with diffuse cutaneous SSc OR diffuse or limited cutaneous SSc AND progressive ILD, AND.",
            "criterions": [
                {
                    "exact_snippets": "diagnosed with diffuse cutaneous SSc",
                    "criterion": "diffuse cutaneous systemic sclerosis (SSc) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "diagnosed with ... diffuse or limited cutaneous SSc",
                    "criterion": "diffuse or limited cutaneous systemic sclerosis (SSc) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive ILD",
                    "criterion": "progressive interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Fulfilling 2013 EULAR/ACR classification criteria for SSc.",
            "criterions": [
                {
                    "exact_snippets": "Fulfilling 2013 EULAR/ACR classification criteria for SSc.",
                    "criterion": "2013 EULAR/ACR classification criteria for systemic sclerosis (SSc)",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii) Participants with severe muscle damage (Physician VAS for muscle damage in Myositis Damage Index > 7 cm on a 10 cm scale), permanent weakness due to a non-IIM cause (eg, stroke), or myositis with cardiac involvement.",
            "criterions": [
                {
                    "exact_snippets": "severe muscle damage (Physician VAS for muscle damage in Myositis Damage Index > 7 cm on a 10 cm scale)",
                    "criterion": "muscle damage",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 7,
                                "unit": "cm"
                            }
                        },
                        {
                            "requirement_type": "scale",
                            "expected_value": "Physician VAS for muscle damage in Myositis Damage Index (10 cm scale)"
                        }
                    ]
                },
                {
                    "exact_snippets": "permanent weakness due to a non-IIM cause (eg, stroke)",
                    "criterion": "permanent weakness due to a non-IIM cause",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "myositis with cardiac involvement",
                    "criterion": "myositis with cardiac involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii) Inadequate response to glucocorticoids and at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, leflunomide, IVIG, and rituximab.",
            "criterions": [
                {
                    "exact_snippets": "Inadequate response to glucocorticoids",
                    "criterion": "response to glucocorticoids",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, leflunomide, IVIG, and rituximab",
                    "criterion": "prior treatment with immunosuppressive or immunomodulatory agents",
                    "requirements": [
                        {
                            "requirement_type": "number of agents used",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "agents"
                            }
                        },
                        {
                            "requirement_type": "duration of use per agent",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "agents used",
                            "expected_value": [
                                "azathioprine",
                                "methotrexate",
                                "cyclosporin A",
                                "tacrolimus",
                                "MMF",
                                "cyclophosphamide",
                                "leflunomide",
                                "IVIG",
                                "rituximab"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), or anti-Sm antibodies at screening.",
            "criterions": [
                {
                    "exact_snippets": "Presence of anti-dsDNA ... at screening",
                    "criterion": "anti-dsDNA antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... anti-histone ... at screening",
                    "criterion": "anti-histone antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... anti-chromatin ... at screening",
                    "criterion": "anti-chromatin antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... anti-Ro (anti-SS-A) ... at screening",
                    "criterion": "anti-Ro (anti-SS-A) antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... anti-La (anti-SS-B) ... at screening",
                    "criterion": "anti-La (anti-SS-B) antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of ... anti-Sm ... at screening",
                    "criterion": "anti-Sm antibodies",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Other protocol-defined Inclusion/Exclusion criteria apply.",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined Inclusion/Exclusion criteria apply.",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Fulfilling the 2017 EULAR/ACR classification criteria for probable or definite IIM.",
            "criterions": [
                {
                    "exact_snippets": "Fulfilling the 2017 EULAR/ACR classification criteria for probable or definite IIM",
                    "criterion": "2017 EULAR/ACR classification criteria for IIM",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "classification",
                            "expected_value": [
                                "probable",
                                "definite"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of drug-induced SLE rather than idiopathic SLE.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of drug-induced SLE",
                    "criterion": "drug-induced SLE",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "rather than idiopathic SLE",
                    "criterion": "idiopathic SLE",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, are excluded.",
            "criterions": [
                {
                    "exact_snippets": "SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, are excluded.",
                    "criterion": "SLE overlap syndromes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "rheumatoid arthritis ... are excluded.",
                    "criterion": "rheumatoid arthritis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "scleroderma ... are excluded.",
                    "criterion": "scleroderma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "mixed connective tissue disease ... are excluded.",
                    "criterion": "mixed connective tissue disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "- IIM disease activity.",
            "criterions": [
                {
                    "exact_snippets": "IIM disease activity",
                    "criterion": "IIM disease activity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Present or recent clinically significant CNS pathology, within 12 months.",
            "criterions": [
                {
                    "exact_snippets": "Present or recent clinically significant CNS pathology, within 12 months.",
                    "criterion": "CNS pathology",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Inadequate response to at least 1 of the following treatments used for at least 3 months: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, or intravenous immunoglobulins (IVIG).",
            "criterions": [
                {
                    "exact_snippets": "Inadequate response to at least 1 of the following treatments ... used for at least 3 months: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, or intravenous immunoglobulins (IVIG).",
                    "criterion": "response to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate"
                        },
                        {
                            "requirement_type": "number of treatments with inadequate response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        },
                        {
                            "requirement_type": "treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "mycophenolate",
                                "cyclophosphamide",
                                "rituximab",
                                "nintedanib",
                                "azathioprine",
                                "tocilizumab",
                                "intravenous immunoglobulins (IVIG)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "- SSc disease activity.",
            "criterions": [
                {
                    "exact_snippets": "SSc disease activity",
                    "criterion": "SSc disease activity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Proof of activity as documented by:.",
            "criterions": [
                {
                    "exact_snippets": "Proof of activity as documented by:",
                    "criterion": "activity",
                    "requirements": [
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) SSc related PAH requiring active treatment.",
            "criterions": [
                {
                    "exact_snippets": "SSc related PAH requiring active treatment",
                    "criterion": "SSc related PAH",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment_status",
                            "expected_value": "requiring active treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Other forms of IIM: Inclusion Body Myositis, Amyopathic DM, any form of juvenile myositis.",
            "criterions": [
                {
                    "exact_snippets": "Inclusion Body Myositis",
                    "criterion": "Inclusion Body Myositis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Amyopathic DM",
                    "criterion": "Amyopathic Dermatomyositis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any form of juvenile myositis",
                    "criterion": "juvenile myositis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "iii) Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.",
            "criterions": [
                {
                    "exact_snippets": "Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.",
                    "criterion": "myositis specific antibody (MSA)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "antibody"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "prior to screening"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.",
                    "criterion": "myositis associated antibody (MAA)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "antibody"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "prior to screening"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Presence of at least 1 myositis specific (MSA), associated antibody (MAA), or ANA at screening or prior to screening.",
                    "criterion": "antinuclear antibody (ANA)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "antibody"
                            }
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "prior to screening"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "A. An active myositis-associated rash OR.",
            "criterions": [
                {
                    "exact_snippets": "An active myositis-associated rash",
                    "criterion": "myositis-associated rash",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "B. A recent muscle biopsy OR.",
            "criterions": [
                {
                    "exact_snippets": "A recent muscle biopsy",
                    "criterion": "muscle biopsy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "i) Fulfilling the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria of SLE.",
            "criterions": [
                {
                    "exact_snippets": "Fulfilling the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria of SLE",
                    "criterion": "systemic lupus erythematosus (SLE) classification criteria",
                    "requirements": [
                        {
                            "requirement_type": "fulfillment",
                            "expected_value": "2019 EULAR/ACR classification criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Diagnosis of Systemic Lupus Erythematosus (SLE) defined as follows:.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of Systemic Lupus Erythematosus (SLE)",
                    "criterion": "Systemic Lupus Erythematosus (SLE) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Other systemic autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded.",
            "criterions": [
                {
                    "exact_snippets": "Other systemic autoimmune diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded.",
                    "criterion": "systemic autoimmune diseases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with type I autoimmune diabetes mellitus ... are not excluded.",
                    "criterion": "type I autoimmune diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ... thyroid autoimmune disease ... are not excluded.",
                    "criterion": "thyroid autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ... Celiac disease ... are not excluded.",
                    "criterion": "Celiac disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with ... secondary Sjögren's syndrome are not excluded.",
                    "criterion": "secondary Sjögren's syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "- SSc disease activity.",
            "criterions": [
                {
                    "exact_snippets": "SSc disease activity",
                    "criterion": "SSc disease activity",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Inadequate response to glucocorticoids and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.",
            "criterions": [
                {
                    "exact_snippets": "Inadequate response to glucocorticoids",
                    "criterion": "response to glucocorticoids",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate"
                        }
                    ]
                },
                {
                    "exact_snippets": "Inadequate response ... to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.",
                    "criterion": "response to immunosuppressive treatments",
                    "requirements": [
                        {
                            "requirement_type": "response",
                            "expected_value": "inadequate"
                        },
                        {
                            "requirement_type": "number of treatments with inadequate response",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "treatments"
                            }
                        },
                        {
                            "requirement_type": "treatment duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "treatment agents",
                            "expected_value": [
                                "cyclophosphamide",
                                "mycophenolic acid or its derivatives",
                                "belimumab",
                                "azathioprine",
                                "anifrolumab",
                                "methotrexate",
                                "rituximab",
                                "obinutuzumab",
                                "cyclosporin",
                                "tacrolimus",
                                "voclosporin"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "ii) Rapidly progressive SSc related lower GI (small and large intestines) involvement (requiring parenteral nutrition); active gastric antral vascular ectasia.",
            "criterions": [
                {
                    "exact_snippets": "Rapidly progressive SSc related lower GI (small and large intestines) involvement (requiring parenteral nutrition)",
                    "criterion": "lower GI involvement related to SSc",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": "rapidly progressive"
                        },
                        {
                            "requirement_type": "requirement for parenteral nutrition",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active gastric antral vascular ectasia",
                    "criterion": "gastric antral vascular ectasia",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "D. Participants diagnosed IIM AND progressive Interstitial Lung Disease (ILD) on high-resolution computed tomography (HRCT)",
            "criterions": [
                {
                    "exact_snippets": "Participants diagnosed IIM",
                    "criterion": "idiopathic inflammatory myopathy (IIM) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "progressive Interstitial Lung Disease (ILD) on high-resolution computed tomography (HRCT)",
                    "criterion": "progressive interstitial lung disease (ILD) on HRCT",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "diagnosis_method",
                            "expected_value": "high-resolution computed tomography (HRCT)"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Inclusion Criteria",
            "criterions": []
        },
        {
            "line": "Exclusion Criteria",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}